Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Metabolic Syndrome × Genitourinary × Clear all

Phase

Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 450 Urinary Bladder Neoplasms 126 Carcinoma, Renal Cell 107 Neoplasms 56 Kidney Neoplasms 47 Non-Muscle Invasive Bladder Neoplasms 39 Neoplasm Metastasis 35 Carcinoma, Transitional Cell 34 Testicular Neoplasms 24 Breast Neoplasms 24 Recurrence 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Wilms Tumor 13 Testicular Germ Cell Tumor 11 Seminoma 11 Pain 11 Ovarian Neoplasms 10 Multiple Myeloma 10 Carcinoma 10 Burkitt Lymphoma 10 Teratoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Osteoporosis 9 Lymphoma, Large B-Cell, Diffuse 9 Lung Neoplasms 9 Urologic Neoplasms 8 Urethral Neoplasms 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Mantle-Cell 8 Lymphoma, Large-Cell, Immunoblastic 8

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03031821 2024-10-04

PRIME

Canadian Urologic Oncology Group

Phase 3 Terminated

Prostatic Neoplasms, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡